B. Riley Securities Reiterates Buy on Orchestra BioMed Hldgs, Raises Price Target to $12
Benzinga Newsdesk 2 days ago
Analyst RatingsNewsReiterationPrice Target
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
B. Riley Securities analyst Madison El-Saadi reiterates Orchestra BioMed Hldgs (NASDAQ:OBIO) with a Buy and raises the price target from $11 to $12.
B. Riley Securities analyst Madison El-Saadi reiterates Orchestra BioMed Hldgs (NASDAQ:OBIO) with a Buy and raises the price target from $11 to $12.
